YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Today's top biotech gainers include Virax Biolabs, following its agreement with Fosun Diagnostics; Forte Biosciences, after reporting positive vitiligo data; Connect Biopharma, with a key near-term catalyst ahead; and SANUWAVE…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell t…
(RTTNews) - Pre-market trading is offering an early glimpse into biotech stocks likely to attract investor attention this Wednesday. Significant price moves ahead of the opening bell are being driven by clinical trial updates, public and p…
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflamm…
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts across therapeutic areas like Psoriasis, Asthma, C…
(RTTNews) - Connect Biopharma Holding Limited (CNTB) surged 13% in pre-market trading Monday after the company issued three major announcements, including positive clinical data for Rademikibart in asthma, COPD and atopic dermatitis, along…
(RTTNews) - Connect Biopharma Holdings (CNTB) reported positive topline preliminary results for its Phase 1 clinical pharmacology study evaluating intravenous rademikibart, the next-generation, anti-interleukin-4-receptor alpha antibody. R…
Major stock indexes saw a significant rebound recently, with the Dow Jones adding 450 points after President Trump ruled out the use of force in Greenland. Amidst this backdrop of market volatility and geopolitical tensions, investors are…
(RTTNews) - Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate updates and investor momentum. Plus Therapeut…
As the U.S. stock market continues to rally, with major indexes like the S&P 500 and Dow Jones nearing record highs, investors are increasingly looking for opportunities in less traditional areas. Penny stocks, though often considered a re…
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of…
On November 4, 2025, major U.S. stock indexes closed sharply lower, with tech stocks leading the decline and Bitcoin experiencing a notable drop. In such volatile market conditions, investors often seek out opportunities that might offer b…
As U.S. stock indexes continue to rise, even amid a government shutdown, investors are keeping a close eye on market dynamics and economic indicators. In this context, penny stocks—despite the somewhat outdated term—remain an intriguing in…
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of infla…
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT STI [https://www.chartmill.com/stock/quote/STI/…
As the U.S. stock market retreats from record highs, driven by a downturn in tech stocks, investors are reevaluating their strategies amidst fluctuating economic indicators and potential interest rate adjustments. In this climate, penny st…
* Connect Biopharma press release [https://seekingalpha.com/pr/20199580-connect-biopharma-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:CNTB [https://seekingalpha.com/symbol/CNTB]): Q2 GAAP EPS of -$0.…
Investing.com - Northland has reiterated its Outperform rating on Connect Biopharma Holdings Ltd (NASDAQ:CNTB), maintaining its price target of $7.50 per share. The stock has shown remarkable momentum, surging 37% in the past week and 45%…
Investing.com -- Connect Biopharma Holdings Ltd (NASDAQ:CNTB) stock jumped 6.4% after the clinical-stage biopharmaceutical company announced plans to terminate its American Depositary Receipts (ADR) program and directly list its ordinary s…
SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammator…
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of…
(RTTNews) - Connect Biopharma Holdings Limited (CNTB), a clinical-stage biopharmaceutical company focused on inflammatory disease treatments, announced that it has regained compliance with Nasdaq's minimum bid price requirement under Listi…
SAN DIEGO - Connect Biopharma Holdings Limited (NASDAQ:CNTB), a $90 million market cap clinical-stage biopharmaceutical company, has regained compliance with Nasdaq’s minimum bid price requirement, the company announced Thursday. The compa…
Over the last 7 days, the United States market has remained flat, but it has risen by 10% over the past 12 months with earnings forecasted to grow by 15% annually. In light of these conditions, identifying stocks that combine value and gro…
SAN DIEGO - Connect Biopharma Holdings Limited (NASDAQ:CNTB), a biotech company with a market capitalization of $63 million and a strong financial health rating according to InvestingPro, announced Wednesday that its collaborator Simcere P…
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data support…
* Connect Biopharma (NASDAQ:CNTB [https://seekingalpha.com/symbol/CNTB]) filed $300M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10086797] MORE ON CONNECT BIOPHARMA * Connect Biopharma receives Nasdaq non-compliance n…
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and…
– Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerba…
– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL) receiving rademikib…
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chr…
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves in…
Connect Biopharma Holdings Limited Simcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater China Connect Biopharma retains rights to develop and commercialize radem…
Simcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater China Connect Biopharma retains rights to develop and commercialize rademikibart in all other markets and co…
Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose mai…
SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the live…